SIC
MGNX icon

Salem Investment Counselors’s MacroGenics MGNX Stock Holding History

Salem Investment Counselors’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200
Closed -$3K – 1066
2021
Q4 		$3K Hold
200
– – ﹤0.01% 974
2021
Q3 		$4K Buy
+200
New +$4.82K ﹤0.01% 866

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Salem Investment Counselors's MGNX Position: Q1 2022 in Review

Salem Investment Counselors sold out of MacroGenics (MGNX) in Q1 2022, closing a stake of 200 shares — an estimated $3K sold.

Salem Investment Counselors first reported a position in MGNX in Q3 2021 and held it in 2 quarters. The position peaked at $4K in Q3 2021. 144 funds tracked by Wall St. Rank hold MGNX as of Q1 2022.

  • Salem Investment Counselors reported no remaining MacroGenics position as of Q1 2022 after selling out during the quarter.
  • Salem Investment Counselors sold 200 MacroGenics shares in Q1 2022, an estimated $3K.
  • Salem Investment Counselors first reported a position in MacroGenics in Q3 2021 and held it in 2 quarters.
  • Salem Investment Counselors's MacroGenics position peaked at $4K in Q3 2021.
  • 144 funds tracked by Wall St. Rank held MacroGenics as of Q1 2022.

Based on Salem Investment Counselors's 13F filing for Q1 2022, filed 16 May 2022.